Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 6/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.42 |
| ▸ | TK1 | P04183 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22340207 | 0.94 | POLB (0.41) | IMPDH2TAS1R3TAS1R1POLBIMPDH1 | |
| SCHEMBL22340317 | 0.85 | RNASEL (0.47) | TAS1R3TAS1R1POLBP2RY1 | |
| SCHEMBL22340083 | 0.81 | POLB (0.45) | TAS1R3TAS1R1POLBP2RY1 | |
| SCHEMBL21132941 | 0.78 | POLB (0.67) | IMPDH2TAS1R3TAS1R1POLBIMPDH1 | |
| SCHEMBL20324606 | 0.78 | POLB (0.67) | IMPDH2TAS1R3TAS1R1POLBIMPDH1 | |
| SCHEMBL9856344 | 0.78 | POLB (0.67) | IMPDH2TAS1R3TAS1R1POLBIMPDH1 | |
| SCHEMBL22340256 | 0.78 | ALDH1A1 (0.39) | IMPDH2TAS1R3TAS1R1POLBIMPDH1 | |
| SCHEMBL22340091 | 0.76 | POLB (0.55) | POLBP2RY1 | |
| SCHEMBL21132767 | 0.76 | P2RX3 (0.56) | IMPDH2TAS1R3TAS1R1POLBIMPDH1 | |
| SCHEMBL24060675 | 0.74 | DTYMK (0.52) | POLBP2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953032-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200253997-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253997-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | IMPDH2 67/4885TAS1R3 4703/4885TAS1R1 4643/4885 |
| US-10953032-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | IMPDH2 67/4885TAS1R3 4703/4885TAS1R1 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.